These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21169898)

  • 21. Suicidal ideation associated with duloxetine use: a case series.
    Parikh AR; Thatcher BT; Tamano EA; Liskow BI
    J Clin Psychopharmacol; 2008 Feb; 28(1):101-2. PubMed ID: 18204351
    [No Abstract]   [Full Text] [Related]  

  • 22. Duloxetine for the treatment of major depressive disorder in older patients.
    Nelson JC; Wohlreich MM; Mallinckrodt CH; Detke MJ; Watkin JG; Kennedy JS
    Am J Geriatr Psychiatry; 2005 Mar; 13(3):227-35. PubMed ID: 15728754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis.
    Spielmans GI
    Psychother Psychosom; 2008; 77(1):12-6. PubMed ID: 18087203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Physical recovery is part of remission].
    Krankenpfl J; 2004; 42(3-4):110. PubMed ID: 15311907
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.
    Brecht S; Courtecuisse C; Debieuvre C; Croenlein J; Desaiah D; Raskin J; Petit C; Demyttenaere K
    J Clin Psychiatry; 2007 Nov; 68(11):1707-16. PubMed ID: 18052564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A word of caution about the implied role for duloxetine in pain management.
    Leo RJ
    J Clin Psychiatry; 2003 Oct; 64(10):1270. PubMed ID: 14658982
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
    Thase ME; Pritchett YL; Ossanna MJ; Swindle RW; Xu J; Detke MJ
    J Clin Psychopharmacol; 2007 Dec; 27(6):672-6. PubMed ID: 18004135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duloxetine's effects in resting functional magnetic resonance imaging of first-episode, drug-naive major depressive disorder with panic disorder patients.
    Lai CH
    J Neuropsychiatry Clin Neurosci; 2011; 23(3):E10-1. PubMed ID: 21948903
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy.
    Barkin RL; Barkin S
    Am J Ther; 2005; 12(5):431-8. PubMed ID: 16148429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypogonadism and gynecomastia with duloxetine.
    Weydt P; Schönfeldt-Lecuona CJ; Gahr M; Connemann BJ
    Pharmacopsychiatry; 2011 Mar; 44(2):77. PubMed ID: 21298612
    [No Abstract]   [Full Text] [Related]  

  • 31. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
    Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
    J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine.
    Pitchot W; Scantamburlo G; Ansseau M
    Psychiatr Danub; 2010 Nov; 22 Suppl 1():S106-7. PubMed ID: 21057413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duloxetine and care management treatment of older adults with comorbid major depressive disorder and chronic low back pain: results of an open-label pilot study.
    Karp JF; Weiner DK; Dew MA; Begley A; Miller MD; Reynolds CF
    Int J Geriatr Psychiatry; 2010 Jun; 25(6):633-42. PubMed ID: 19750557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability.
    Karp JF; Whyte EM; Lenze EJ; Dew MA; Begley A; Miller MD; Reynolds CF
    J Clin Psychiatry; 2008 Mar; 69(3):457-63. PubMed ID: 18251622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder.
    Herrera-Guzmán I; Herrera-Abarca JE; Gudayol-Ferré E; Herrera-Guzmán D; Gómez-Carbajal L; Peña-Olvira M; Villuendas-González E; Joan GO
    Psychiatry Res; 2010 May; 177(3):323-9. PubMed ID: 20385412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duloxetine's role in the treatment of depression and associated painful physical symptoms.
    Wohlreich MM; Watkin JG; Gonzales JS
    J Clin Psychiatry; 2004 Jul; 65(7):1018-9. PubMed ID: 15291696
    [No Abstract]   [Full Text] [Related]  

  • 37. Attributes of response in depressed patients switched to treatment with duloxetine.
    Sagman D; McIntosh D; Lee MS; Li H; Ruschel S; Hussain N; Granger RE; Lee AC; Raskin J
    Int J Clin Pract; 2011 Jan; 65(1):73-81. PubMed ID: 21078010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Burning paresthesia related to duloxetine therapy.
    Woo YS; Bahk WM
    J Clin Psychopharmacol; 2014 Jun; 34(3):392-4. PubMed ID: 24633002
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine.
    Joffe H; Soares CN; Petrillo LF; Viguera AC; Somley BL; Koch JK; Cohen LS
    J Clin Psychiatry; 2007 Jun; 68(6):943-50. PubMed ID: 17592922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Digging for data on harms in duloxetine trials.
    Doshi P; Zito J; dosReis S
    BMJ; 2014 Jun; 348():g3578. PubMed ID: 24904123
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.